How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

In Brief

Thyme Care triples multidisciplinary care team with increased focus on survivorship

Thyme Care expanded its survivorship program and comprehensive cancer care services with the appointment of two experienced medical directors: Asma Dilawari as medical director of oncology care, who will lead the company’s survivorship program expansion, and Nelia Jain as medical director of palliative care, who will scale Thyme Care’s virtual palliative care offering, called Enhanced Supportive Care.

June 13, 2025

Vol.51 No.23

Clinical Roundup

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT Southwestern published in Nature.

June 13, 2025

Vol.51 No.23

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Clinical Roundup

New biomarker may guide best use of KRAS inhibitors in lung cancer

Researchers from the University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer, following treatment with the KRAS targeted therapy, sotorasib.

May 30, 2025

Vol.51 No.21

In Brief

In memoriam: Barbara Summers, former chief nursing officer at MD Anderson

Barbara Summers, a pioneering nurse leader, mentor and champion of patient-centered care, died May 6, in Richmond, Virginia, surrounded by her family.

May 23, 2025

Vol.51 No.20

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

YOU MAY BE INTERESTED IN

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Thyme Care triples multidisciplinary care team with increased focus on survivorship

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

New biomarker may guide best use of KRAS inhibitors in lung cancer

In memoriam: Barbara Summers, former chief nursing officer at MD Anderson

Renew today!

Subscriber content

Never miss an issue!

Login